JAK Inhibitors in Skin of Color Beyond
On-Demand Video
Event Details
Skin of Color Society 19th Annual Skin of Color Society Scientific Symposium
Where Science, Innovation, & Inclusion Meet
Presented and recorded on March 16, 2023 in New Orleans, LA
Non-CME
Panel: JAK Inhibitors in Skin of Color Beyond Atopic Dermatitis
Moderator
Brett Andrew King, MD, PhD, FAAD
Associate Professor of Dermatology
Yale School of Medicine
Dr. Brett Andrew King is professor of dermatology at Yale School of Medicine, specializing in inflammatory skin diseases. He has pioneered the use of Janus kinase (JAK) inhibitors in dermatology, and his work has revealed the broad utility of JAK inhibitors for the treatment of alopecia areata, vitiligo, atopic dermatitis, granulomatous disorders, and other conditions.
Panelists
William Damsky, MD, PhD, FAAD
Assistant Professor of Dermatology and Pathology
Yale School of Medicine
Dr. William Damsky specializes in evaluation and treatment of patients with inflammatory skin disorders, especially cutaneous granulomatous diseases such as sarcoidosis and granuloma annulare. As a physician-scientist with training in basic immunology, Dr. Damsky’s laboratory leverages the latest immunologic approaches to understand mechanisms of inflammatory skin disease and how they are affected by novel therapies.
Dr.Damsky’s research has been supported by Career Development Awards from the Dermatology Foundation and the National Institute of Allergy and Infectious Diseases. He is a recipient of the Young Investigator Award from both the American Academy of Dermatology and American Society for Clinical Investigation for his research in novel therapeutics for sarcoidosis.
John E. Harris, MD, PhD
Professor and Chair, Department of Dermatology
Founding Director, Vitiligo Clinic and Research Center
Founding Director, Autoimmune Therapeutics Institute
Dr. John E. Harris is Chair of Dermatology, Director of the Autoimmune Therapeutics Institute, and Director of the Vitiligo Clinic and Research Center at UMass Chan Medical School. He is a dermatologist and physician-scientist, caring for patients in a vitiligo specialty clinic and running a research laboratory focused on understanding disease pathogenesis and developing new treatments. His group integrates basic, translational, and clinical research strategies to accomplish this. As a result, clinical trials in vitiligo have shown success. Dr. Harris founded Villaris Therapeutics (acquired by Incyte in 2022) and 3 other companies to develop treatments for inflammatory skin diseases.